On July 16, 2026, women's health company Juno Bio announced it has raised $3.8 million to open its first sequencing lab — a CLIA-certified, women's-health-focused facility in Oakland, California — and bring its at-home vaginal microbiome test in-house. The round was backed by Ada Ventures, Artesian, Entrepreneur First, and the Illumina Accelerator. Juno Bio's test screens for all bacteria and fungi in the vaginal microbiome, returns an analysis of the microbes present and the conditions associated with them (such as bacterial vaginosis or yeast infections), and can also screen for sexually transmitted infections including chlamydia and gonorrhea, followed by a free consult call. It's available in 46 states at $149 for a one-off or $99 per test on a quarterly plan.

Why It Matters

The vaginal microbiome is quietly becoming one of femtech's most consequential frontiers, sitting at the intersection of sexual health, fertility, STI screening, and — as femtech firm Daye argued days earlier — even cervical cancer risk modeling. Juno Bio building its own CLIA-certified lab matters because control of the sequencing pipeline is what turns a consumer test into a defensible clinical-data asset: proprietary datasets, faster turnaround, and the ability to develop validated "measurement standards" that clinicians and payers might eventually adopt. For investors, it's another data point that women's-health diagnostics can scale capital-efficiently, reinforcing the broader 2025–26 thesis that women's health is a maturing asset class rather than a niche. And for consumers frustrated by misdiagnosed BV and yeast infections, at-home microbiome testing is part of the same destigmatizing, direct-to-consumer wave — spanning at-home STI kits and hormone wearables — that is pulling intimate healthcare out of the clinic and onto the bathroom counter.

The capital is explicitly aimed at vertical integration. Moving sequencing in-house, the company told MedCity News, gives it more control over quality, speed, innovation, and future R&D — a notable step for a category that has historically relied on third-party labs. "The vaginal microbiome is still one of the least understood systems in the body at a clinical scale. With our lab, we're starting to build a measurement standard that clinicians can actually use," said founder and chief science officer Leighton Turner. CEO and founder Hana Janebdar framed the next chapter as scaling access and "continuing to close the gender health gap."

Juno Bio's pitch leans on a striking data point about the status quo it's trying to displace: the company says that before using its at-home test, 67.5% of its customers had been incorrectly diagnosed and only 13% had been successfully treated. Investor Check Warner of Ada Ventures praised the team's capital efficiency and clinical infrastructure in "a critically underserved category." Juno Bio isn't alone in the space — New York-based Evvy also offers an at-home vaginal microbiome test — signaling that microbiome-based intimate diagnostics is maturing from a novelty into a competitive femtech sub-sector.

Sources

Update — 2026-07-18

Initial entry — story first created.